Company Information

Company Profile

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Contact Information

Investor Relations
Oasmia Pharmaceutical AB
Anders Blom
Executive Vice President
Vallongatan 1
752 28, Uppsala
Sweden
T: +46 18 50 54 40
anders.blom@oasmia.com

Company Contact
Oasmia Pharmaceutical AB
Vallongatan 1
Uppsala, 752 28